about us
EDDU
Early Drug Discovery Unit (EDDU) at the University of Barcelona
Transfer Projects
- Dual-acting molecules as an innovative analgesic strategy to treat pain. CC22-10176CONSOLIDATE.
Fundació Caixa de Pensions ‘La Caixa’. Amount: 300.000 €. - Progression of an innovative antiglioblastoma drug. 2024 PROD 00007 –
Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) – Ajuts d’Indústria del Coneixement per a l’any 2024. Amount: 132.000 euros. - Preclinical progression of a structurally new anti-glioblastoma drug. 2023 LLAV 00050 –
Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR)- Ajuts d’Indústria del Coneixement per a l’any 2023. Amount: 20.000 euros. - Preclinical progression of a structurally new antiglioblastoma drug. F2I PdC_2023-003.
Ajusts Prova de Concepte (PdC) dins del Fons per a l’impuls de la Innovació (F2I). Amount 25.000 euros. - A first-in-class anti-Alzheimer lead that blocks multiple early disease mechanisms. 2023 PROD 00079 –
Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) – Indústria del Coneixement per l’any 2023. Amount: 150.000 €. - Phosphoiminoproline LPIP, a Disease-Modifying Drug for Alzheimers Disease. Proof of concept PDC2022-133441-I00. Ministerio de Ciencia e Innovación. Amount: 130.000 euros
- Noves molècules duals: una estratègia innovadora pel tractament del dolor crònic. 2021PROD00181 – Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) – Ajuts d’Indústria del Coneixement per a l’any 2022. Amount: 99.986,25 €.
- Una nova classe de compostos que bloquegen múltiples mecanismes inicials de malaltiesneurodegeneratives. 2021LLAV00082. Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) _ Ajuts d’Indústria del Coneixement per a l’any 2021. Amount: 20.000 €.
Patents
- Dual G9a/GSK-3β inhibitors. Patent application: WO2025/215108A1 (priority date: April 10, 2024).
- Morpholine and 1,4-oxazepane compounds and its use in therapy. Patent application: WO2024/261340 (priority date: June 22, 2023).
- Dual inhibitors for the treatment of Alzheimer’s disease. Patent application: WO2024/184305A1 (priority date: March 3, 2023).
- Synergistic combinations of a sigma-1 receptor (S1R) and a soluble epoxide hydrolase inhibidor (sEHI) and their use in the treatment of pain. Patent application: WO2024/105225A1 (priority date: Nov 18, 2022).
- Dual inhibitors of sigma-1 receptor and soluble epoxide hydrolase and their use in the treatment of pain. Patent application: WO2024/105234A1 (priority date: Nov 18, 2022).
- Synthetic I2 imidazoline receptor ligands for prevention or treatment of human brain disorders. Patent application: US2022/064195A1 (priority date: June 14, 2021).
- Compounds for use in the treatment of hyperproliferative disorders. Patent application: WO2022/223704A1 (priority date: April 21, 2021).
Exploration
- Compounds as soluble epoxide hydrolase inhibitors. Patent applications: WO2017/182464A1 (priority date: April 17, 2016). Licensed to an undisclosed US-based company.
- New aza-tetracyclo derivatives. Patent applications: WO2019/243414A1 (priority date: June 20, 2018) & WO2022/200105A1 (priority date: March 3, 2021). Licensed to CIDQO 2012
- Creation of the spin-off Oniria Therapeutics (Dec 23, 2021).
Industrial Doctorates
- 2024 DI 00023, Oniria Therapeutics “Design, synthesis and biophysical characterization of TET2 inhibitors”.
- 2018 DI 070, Biopharma Synergies, S. L. “Noves aproximacions sintètiques a productes orgànics d’interès farmacèutic”
Clients and collaborators
